Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

AGM Statement

19 Jun 2013 14:00

RNS Number : 4028H
Surgical Innovations Group PLC
19 June 2013
 



 

 

Surgical Innovations Group plc

("SI" or the "Group" or the "Company")

 

AGM Statement

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), held its Annual General Meeting today at 2.00pm at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ, during which the Chairman, Doug Liversidge CBE, made the following statement:

 

"We are pleased to report that the Company is delivering on a number of key areas. In the UK, we are seeing strong demand for our YelloPort+plus™ valve and swingtop products where our cost effective solutions are proving appealing to Healthcare Trusts across the country, with cost reduction as a primary objective. Since the start of the financial year a further 15 hospitals have been converted to the YelloPort+plus™ system, including eight since we last updated shareholders in our Preliminary Results announcement on 9 April 2013. In addition eight hospitals were converted to using Logi™Cut scissors since the start of the year. It is worth noting that this increased success in our home market provides a helpful boost for our international growth prospects.

 

Our commitment to expand our US direct sales and marketing operations was confirmed by the appointment of Rick Barnett as President of US Sales and Operations. The US is a very important market for us, and we were pleased to announce our first new US dealer following Rick's appointment. Sales of our products through our US OEM partners are in-line with our expectations and we have been pleased with reports from CareFusion that evaluations of the 3mm PretzelFlex® have been positive. Sales of 5mm PretzelFlex® in the US are performing as expected and CareFusion have recently ordered additional complementary FastClamp™ stock.

 

We continue to expand our Clinical Advisory Board ('CAB') of national and international experts through two new appointments to the CAB since the year end. Not only are members of the CAB chosen as key opinion leaders in their respective fields and countries, they also provide the Group with invaluable clinical insight into the development of new products. As already reported, we have seen successful pilot testing of our hip arthroscopy prototype and we are pleased with the functionality of the product and our overall progress in this area. Furthermore, our development of a hernia mesh fixation device for Advanced Medical Solutions Group plc is progressing well and is in the final stages of testing and evaluation.

 

In May, we were also able to announce a further order of £210,000 from our long standing industrial partner to develop a non-medical application of our patented segment technology. If the development project is successful we expect to sell a number of these devices for this application in 2014.

 

Our performance since the start of the year has been encouraging, showing good growth across the business."

 

Enquiries:

 

Surgical Innovations Group plc

www.sigroupplc.com

Doug Liversidge, Non-Executive Chairman

Tel: +44 (0) 113 230 7597

Graham Bowland, Chief Executive Officer

graham.bowland@surginno.co.uk

 

 

Panmure Gordon (Nominated Advisor & Broker)

www.panmure.com

Freddy Crossley / Fred Walsh (Corporate Finance)

Tel: +44 (0) 20 7886 2500

Adam Pollock/ Victoria Boxall (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or si@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Notes to Editors:

 

About Surgical Innovations Group plc

 

Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets.

 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

 

Over 100 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

 

The Group's patented products are sold through three main channels:

 

SI brand

Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent.

 

OEM and IP

The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees. Clients include Teleflex Medical, Olympus and CareFusion.

 

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

 

For more information, see www.sigrouplplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSFFFEUFDSEIM
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Apr 20267:00 amRNSFinal Results
9th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Jan 20267:00 amRNSChief Financial Officer update
18th Dec 20257:00 amRNSTrading Update
28th Nov 20257:00 amRNSNew LTIP & Grant of Options
29th Sep 20257:05 amRNSBoard Changes
29th Sep 20257:00 amRNSHalf-year Report
17th Sep 20253:15 pmRNSNotice of Results
27th Jun 20254:42 pmRNSResult of AGM
26th Jun 202511:36 amRNSWithdrawal of AGM Resolutions 9 and 10
4th Jun 20258:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
30th May 20257:00 amRNSFinal Results
10th Apr 20257:00 amRNSTrading update
1st Apr 202511:30 amRNSUpdate on timing of 2024 Full Year results
19th Feb 202510:11 amRNSHolding(s) in Company
17th Feb 20254:12 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSFY24 Trading Update & & Directorship Change
30th Sep 20247:00 amRNSHalf-year Report
10th Sep 20247:00 amRNSNotice of Results
27th Aug 20243:51 pmRNSHolding(s) in Company
27th Aug 20243:49 pmRNSHolding(s) in Company
19th Aug 20241:06 pmRNSHolding(s) in Company
19th Aug 20241:01 pmRNSHolding(s) in Company
29th Jul 202412:18 pmRNSHolding(s) in Company
25th Jul 20244:04 pmRNSHolding(s) in Company
17th Jun 20244:43 pmRNSResult of AGM
10th Jun 20247:00 amRNSDirectorate Change - Appointment of CFO
23rd May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd Apr 20243:34 pmRNSHolding(s) in Company
19th Apr 20246:25 pmRNSHolding(s) in Company
18th Apr 20247:01 amRNSFinal Results
18th Apr 20247:00 amRNSNew exclusive UK distribution agreements secured
9th Apr 20247:00 amRNSDirectorate Change & Notice of Results
29th Jan 20247:00 amRNSYear-end 2023 Trading Update
19th Dec 20237:00 amRNSDirectorate Change
5th Dec 20237:00 amRNSDirectorate Change
19th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTrading Update and Notice of Results
27th Jun 202312:12 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
26th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
25th May 202311:11 amRNSDirector/PDMR Shareholding - Replacement
25th May 20237:00 amRNSDirector/PDMR Shareholding
22nd May 20237:00 amRNSDirectorate changes and board succession planning
29th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:00 amRNSNotice of Results and Investor Presentation
23rd Jan 20237:00 amRNSYear-end Trading Update
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.